Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Appointed director
Inv. presentation
Quarterly results
|
|
Amneal Pharmaceuticals, Inc. (AMRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/17/2020 |
8-K/A
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"Consent of Crowe LLP - AvKARE, Inc",
"Consent of Crowe LLP - Dixon-Shane, LLC",
"Audited Financial Statements of AvKARE, Inc. as of December 31, 2019 and for the year then ended",
"Audited Financial Statements of Dixon-Shane, LLC dba R&S Northeast LLC as of December 31, 2019 and for the year then ended",
"Unaudited Pro Forma Condensed Combined Financial Information of Amneal Pharmaceuticals, Inc. as of December 31, 2019 and for the year then ended December 31, 2019" |
|
| 02/20/2020 |
8-K/A
| Quarterly results |
| 02/20/2020 |
8-K/A
| Quarterly results |
| 03/01/2019 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"AMENDMENT NO. 3 TO FORM 8-K",
"Audited consolidated balance sheets of Impax as of December 31, 2017 and December 31, 2016, the related audited consolidated statements of operations, comprehensive (loss) income, changes in stockholders' equity and cash flows for Impax for the years ended December 31, 2017, 2016 and 2015, and the notes and schedule thereto, including the related report of the independent registered public accounting firm thereon",
"Unaudited consolidated balance sheet of Impax as of March 31, 2018, unaudited consolidated statements of operations, comprehensive (loss) income, changes in stockholders' equity and cash flows for Impax for the three months ended March 31, 2018, and the notes thereto",
"Management's Discussion and Analysis of Financial Condition and Results of Operations of Impax for the years ended December 31, 2017 and 2016",
"Management's Discussion and Analysis of Financial Condition and Results of Operations of Impax for the three months ended March 31, 2018 and March 31, 2017",
"Unaudited pro forma condensed combined statements of operations of the Company for the fiscal year ended December 31, 2018" |
|
|
|